By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Mesna (monograph) > Mesna Dosage
Drugs
https://themeditary.com/dosage-information/mesna-dosage-11497.html

Mesna Dosage

Drug Detail:Mesna (monograph) (Mesnex)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Hemorrhagic Cystitis Prophylaxis

This drug may be given on a fractionated dosing schedule of either 3 bolus IV injections or a single injection followed by 2 oral doses. The dosing schedule should be repeated on each day that ifosfamide is administered. When the dose of ifosfamide is adjusted, the ratio of mesna to ifosfamide should be maintained.

IV: Mesna is given at 20% of the ifosfamide dose once at the time of ifosfamide administration and 20% of the ifosfamide dose 4 and 8 Hours after each dose of ifosfamide (e.g., if ifosfamide were given at 1.2 g/m2 at 0 Hours, the dose of mesna would be 240 mg/m2 given at 0, 4, and 8 Hours after ifosfamide)

ORAL (to be given after one dose of IV mesna): Mesna is given at 40% of the ifosfamide dose at 2 and 6 Hours after each dose of ifosfamide (e.g., if ifosfamide were given at 1.2 g/m2 at Hour 0, the IV dose of mesna would be 240 mg/m2 given at the time of ifosfamide administration (0 Hour) and the oral dose of this drug would be 480 mg/m2 given at 2 and 6 Hours after ifosfamide)

Comments:

  • In order to maintain adequate protection, the recommended dosage regimen should be repeated on each day that ifosfamide is administered.
  • When the dosage of ifosfamide is adjusted (either increased or decreased), the dose of mesna should also be modified accordingly.
  • Adequate hydration and sufficient urinary output should be maintained, as required for ifosfamide treatment, and urine should be monitored for the presence of hematuria. If severe hematuria develops when mesna is given according to the recommended dosage schedule, dosage reductions or discontinuation of ifosfamide therapy may be required.

Use: A prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis

Usual Pediatric Dose for Hemorrhagic Cystitis Prophylaxis

Do not give this drug to premature neonates and low-birth weight infants.

This drug may be given on a fractionated dosing schedule of either 3 bolus IV injections or a single injection followed by 2 oral doses. The dosing schedule should be repeated on each day that ifosfamide is administered. When the dose of ifosfamide is adjusted, the ratio of mesna to ifosfamide should be maintained.

IV: Mesna is given at 20% of the ifosfamide dose once at the time of ifosfamide administration and 20% of the ifosfamide dose 4 and 8 Hours after each dose of ifosfamide (e.g., if ifosfamide were given at 1.2 g/m2 at 0 Hours, the dose of mesna would be 240 mg/m2 given at 0, 4, and 8 Hours after ifosfamide)

ORAL (to be given after one dose of IV mesna): Mesna is given at 40% of the ifosfamide dose at 2 and 6 Hours after each dose of ifosfamide (e.g., if ifosfamide were given at 1.2 g/m2 at Hour 0, the IV dose of mesna would be 240 mg/m2 given at the time of ifosfamide administration (0 Hour) and the oral dose of this drug would be 480 mg/m2 given at 2 and 6 Hours after ifosfamide)

Comments:

  • In order to maintain adequate protection, the recommended dosage regimen should be repeated on each day that ifosfamide is administered.
  • When the dosage of ifosfamide is adjusted (either increased or decreased), the dose of mesna should also be modified accordingly.
  • Adequate hydration and sufficient urinary output should be maintained, as required for ifosfamide treatment, and urine should be monitored for the presence of hematuria. If severe hematuria develops when mesna is given according to the recommended dosage schedule, dosage reductions or discontinuation of ifosfamide therapy may be required.

Use: A prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in premature neonates and low-birth weight infants.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Stability:

  • The multidose vials may be stored and used for up to 8 days after initial puncture.
  • Store diluted solutions at 25C (77F) and use within 24 hours.
  • Store tablets in refrigerator at 20C to 25C (68F to 77F), excursions permitted to 15C to 30C (59F to 86F).

General:
  • Do not mix this drug with epirubicin, cyclophosphamide, cisplatin, carboplatin, or nitrogen mustard.
  • The benzyl alcohol contained in the injection vials can reduce the stability of ifosfamide. Ifosfamide and mesna may be mixed in the same bag provided the final concentration of ifosfamide does not exceed 50 mg/mL. Higher concentrations of ifosfamide may not be compatible with mesna and may reduce the stability of ifosfamide.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Any solutions which are discolored, hazy, or contain visible particulate matter should not be used.

PATIENT COUNSELING INFORMATION
  • Advise the patient to discontinue this drug and seek immediate medical attention if they experience a hypersensitivity reaction, including systemic anaphylactic reactions.
  • Advise the patient to take this drug at the exact time and in the exact amount as prescribed.
  • Advise the patient to contact their healthcare provider if they miss a dose or if they vomit within 2 hours of taking the oral formulation.
  • This drug does not prevent hemorrhagic cystitis in all patients nor does it prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide.
  • Advise the patient to report to their healthcare provider if his/her urine turns a pink or red color.
  • Advise the patient to drink 1 to 2 liters of fluid each day during therapy.
  • Advise the patient that Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms and bullous and ulcerative skin and mucosal reactions have occurred.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by